ClinicalTrials.gg
RecruitingNCT07115238Updated Aug 11, 2025

Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD

A Phase 3 interventional study of XTR006 in Alzheimer Disease and Neurofibrillary Tangle, sponsored by Sinotau Pharmaceutical Group. Recruiting at 1 site in China. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by Sinotau Pharmaceutical Group · Phase 3, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 8 months after the study started (first participant enrolled Nov 2024, registered Aug 2025).
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
354
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 260 studies in Alzheimer Disease with a site in China — 150 open to participants now, 162 under way, 21 of them phase 3. Alzheimer Disease · China.

Planned enrollment
35th of 176
354 · median 100
Started
2024
with 40 others
Phase 3
33 of 260
15 open now
Primary completion
2025-12
later than 26 of 161 live
Registered
198th of 260
by date

Among the 260 studies in Alzheimer Disease with a site in China, this one is the 35th largest by planned enrollment of the 176 interventional ones that give a count, is one of 41 that started in 2024, is one of 33 in phase 3, reaches primary completion later than 26 of the 161 other live ones, and was the 198th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

150 of the 260 studies in Alzheimer Disease with a site in China are open now. Recruiting first, the newest first:

145 more — sign in →

All 150 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Alzheimer Disease with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of XTR006 injection PET visual reading in detecting brain neurofibrillary tangles (NFTs) in elderly subjects with Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), and cognitively normal individuals. The main question it aims to answer is:

  • What is the sensitivity and specificity of XTR006 PET visual reading results compared to the truth standard across MCI, AD, and cognitively normal subjects?

Participants will:

  • Receive XTR006 injection
  • Undergo PET/CT scanning
Read the detailed description

This is a multicenter, single-blind, non-randomized phase III study. The study aims to evaluate the effectiveness of XTR006 PET imaging visual reads for detecting NFTs in subjects. The trial procedures for all subjects include a screening period, an administration period, and a follow-up period. All subjects must sign an informed consent form before entering the screening period.

In this study, nuclear medicine physicians with tau-PET image reading experience will undergo training in the XTR006 PET visual reading methodology. Three nuclear medicine physicians who achieve excellent scores on the assessment will be selected as blinded visual readers for this study. All subject images will be visually interpreted in a blinded manner according to the XTR006 PET visual reading methodology. The final reading conclusion will be determined by consensus of at least two blinded visual readers. Using the composite diagnostic results of clinical cognitive assessment and Aβ-PET examination as the reference standard, sensitivity and specificity will be calculated with their 95% confidence intervals. The primary endpoint of this study will be considered achieved if the lower limit of the confidence interval exceeds the target value of 60%. Additionally, this study will analyze PET SUVR across groups to evaluate XTR006 uptake characteristics in different populations from a semi-quantitative perspective and assess the safety of XTR006 through analysis of post-administration AEs and SAEs.

03

Conditions studied

  • Alzheimer Disease
  • Neurofibrillary Tangle

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria for All Subjects:

  1. Male or female subjects aged ≥50 years.
  2. Able to tolerate both PET and MRI examinations.
  3. Must use measures during the study period and for 6 months after study completion.
  4. Written must be obtained before any assessment is performed.

Inclusion Criteria for Cognitively Normal Subjects:

1)CDR (Clinical Dementia Rating) score of 0. 2) (Mini-Mental State Examination) score ≥28. 3)Negative visual reading result on brain Aβ-PET imaging.

Inclusion Criteria for Subjects with MCI:

  1. Meet the core clinical criteria for MCI due to AD according to 2011 NIA-AA (National Institute on Aging-Alzheimer's Association) standards
  2. Positive visual reading result on brain Aβ-PET imaging

Inclusion Criteria for Subjects with AD:

  1. Meet the specific clinical phenotype criteria for typical AD according to 2014 International Working Group (IWG)-2 standards:
  2. Positive visual reading result on brain Aβ-PET imaging.

Exclusion Criteria:

  1. Diagnosis of atypical AD, frontotemporal lobar degeneration (FTLD), Lewy body dementia, or other types of dementia.
  2. Current significant psychiatric illness with symptoms that prevent completion of imaging procedures.
  3. MRI-confirmed structural brain abnormalities, such as large stroke or intracranial mass lesions.
  4. Claustrophobia.
  5. History of alcohol abuse or drug abuse/dependence.
  6. Allergy to the study drug or any of its components.
  7. Women who are currently breastfeeding.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
354 participants (estimated)

Study arms

  • Experimental
    Alzheimer's Disease

    AD subjects will undergo PET imaging using \[18F\]XTR006.

    Drug: XTR006

  • Experimental
    Mild Cognitive Impairment Due to Alzheimer's Disease

    MCI subjects will undergo PET imaging using \[18F\]XTR006.

    Drug: XTR006

  • Experimental
    Cognitively normal

    Cognitively normal subjects will undergo PET imaging using \[18F\]XTR006.

    Drug: XTR006

Interventions

  • DrugXTR006

    all patients will receive one injection of \[18F\]XTR006, a PET radiopharmaceutical selective for NFTs. For the injection, subjects will receive a target dose of 4-6 mCi IV as a bolus injection. \[18F\]XTR006 injection will be followed by a 10 ml saline flush.

    Also known as: [18F]MK 6240, Florquinitau

06

What researchers measure

Primary outcomes

  1. Evaluate the effectiveness of visual reading of XTR006 PET imaging in detecting tau NFTs (neurofibrillary tangles)

    The sensitivity and specificity of XTR006 PET imaging visual reading results compared to the truth standard.

    Time frame: 12month

Secondary outcomes

  1. Compare the overall brain uptake patterns of XTR006 in MCI (Mild Cognitive Impairment), AD (Alzheimer's Disease), and cognitively normal subjects.

    The inter-group differences in XTR006 PET Standardized Uptake Value Ratios (SUVR) within brain regions of interest(ROIs) among different subject groups;The sensitivity and specificity of semi-quantitative SUVR analysis in differentiating between different subject groups.

    Time frame: 12month

  2. Safety and Tolerability Profile Measured by Adverse Events (AEs)

    Safety and tolerability profile for the administration of \[18F\]XTR006 and PET scanning are measured by number of participants with adverse events (AEs).

    Time frame: 12month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2025, 13 months after the start.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's planned 13 months is below that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 11, 2025
StartActual
Nov 20, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jun 30, 2026
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07115238
Lead sponsor
Sinotau Pharmaceutical Group
Responsible party
Sponsor
First posted
Aug 11, 2025
Start date
Nov 20, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Aug 11, 2025

Study contacts

Jiong Shi, Doctor
Contact
jshi2022@ystc.edu.cn
15512191857
Ruiming Wang, Doctor
Contact
wrm@yeah.net
13501151740
Jiong Shi, Doctor
principal investigator · The First Affiliated Hospital of University of Science and Technology of China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion